1
|
Antonazzo IC, Cortesi PA, Zanon E, Pasca S, Morfini M, Santoro C, De Cristofaro R, Di Minno G, Cozzolino P, Mantovani LG. Personalized Prophylaxis with myPKFiT CE: A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients. Medicina (Kaunas) 2023; 60:34. [PMID: 38256294 PMCID: PMC10820281 DOI: 10.3390/medicina60010034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 12/18/2023] [Accepted: 12/21/2023] [Indexed: 01/24/2024]
Abstract
Background and Objectives: This study aimed to assess the effectiveness and costs associated with pharmacokinetics-driven (PK) prophylaxis based on the myPKFiT® device in patients affected by hemophilia A (HA) in Italy. Materials and Methods: An observational retrospective study was conducted in three Italian hemophilia centers. All patients with moderate or severe HA, aged ≥ 18 years, capable of having PK estimated using the myPKFiT device, and who had had a clinical visit between 1 November 2019 and 31 March 2022 were included. Differences in clinical, treatment, health resources, and cost data were assessed comparing post-PK prophylaxis with pre-PK. The incremental cost-effectiveness ratio (ICER) was estimated as cost (EUR) per bleed avoided. Results: The study enrolled 13 patients with HA. The mean annual bleeding rate decreased by -1.45 (-63.80%, p = 0.0055) after the use of myPKFiT®. Overall, the consumption of FVIII IU increased by 1.73% during follow-up compared to the period prior the use of the myPKFiT. Prophylaxis based on the myPKFiT resulted in an ICER of EUR 5099.89 per bleed avoided. Conclusions: The results of our study support the idea that the use of PK data in clinical practice can be associated with an improvement in the management of patients, as well as clinical outcomes, with a reasonable increase in costs.
Collapse
Affiliation(s)
- Ippazio Cosimo Antonazzo
- Research Centre on Public Health (CESP), University of Milan-Bicocca, 20900 Monza, Italy; (P.A.C.); (L.G.M.)
- IRCCS Istituto Auxologico Italiano, 20145 Milano, Italy
| | - Paolo Angelo Cortesi
- Research Centre on Public Health (CESP), University of Milan-Bicocca, 20900 Monza, Italy; (P.A.C.); (L.G.M.)
- IRCCS Istituto Auxologico Italiano, 20145 Milano, Italy
| | - Ezio Zanon
- Hemophilia Center, University Hospital of Padua, 35128 Padua, Italy;
| | - Samantha Pasca
- Laboratory Medicine, Department of Biomedical Sciences, Padua University Hospital, 35128 Padua, Italy;
| | - Massimo Morfini
- Italian Association of Haemophilia Centres—AICE, 50100 Firenze, Italy;
| | | | - Raimondo De Cristofaro
- Center for Haemorrhagic and Thrombotic Diseases, Department of Medical Sciences, Catholic University School of Medicine, ‘A. Gemelli’ Hospital, 00168 Rome, Italy;
| | - Giovanni Di Minno
- Department of Clinical Medicine and Surgery, Regional Service Centre of Coagulation Disorders, ‘Federico II’ University, 80138 Naples, Italy;
| | - Paolo Cozzolino
- Research Centre on Public Health (CESP), University of Milan-Bicocca, 20900 Monza, Italy; (P.A.C.); (L.G.M.)
| | - Lorenzo Giovanni Mantovani
- Research Centre on Public Health (CESP), University of Milan-Bicocca, 20900 Monza, Italy; (P.A.C.); (L.G.M.)
- IRCCS Istituto Auxologico Italiano, 20145 Milano, Italy
| |
Collapse
|